JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Broom, D. C.
Right arrow Articles by Traynor, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Broom, D. C.
Right arrow Articles by Traynor, J. R.

Vol. 303, Issue 2, 723-729, November 2002

Comparison of Receptor Mechanisms and Efficacy Requirements for delta -Agonist-Induced Convulsive Activity and Antinociception in Mice

Daniel C. Broom, Joshua F. Nitsche, John E. Pintar, Kenner C. Rice, James H. Woods and John R. Traynor

Departments of Pharmacology (D.C.B., J.H.W., J.R.T.) and Psychology (J.H.W.), University of Michigan Medical School, Ann Arbor, Michigan; Department of Neuroscience and Cell Biology (J.F.N., J.E.P.), Robert Wood Johnson Medical School, Piscataway, New Jersey; and National Institute of Diabetes and Digestive and Kidney Diseases (K.C.R.), National Institutes of Health, Bethesda, Maryland

delta -Opioid receptor-selective agonists produce antinociception and convulsions in several species, including mice. This article examines two hypotheses in mice: 1) that antinociception and convulsive activity are mediated through the same type of delta -receptor and 2) that greater delta -agonist efficacy is required for antinociception than for convulsive activity. delta -Mediated antinociception was evaluated in the acetic acid-induced abdominal constriction assay, which involves a low-intensity noxious stimulus; convulsive activity was indicated as a mild tonic-clonic convulsive episode followed by a period of catalepsy. In delta -opioid receptor knockout mice [DOR-1(-/-)], the nonpeptidic delta -agonists (±)-4-[(R*)-[(2S*,5R*)-2,5-dimethyl-4-(2-propenyl)-1- piperazinyl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide hydrochloride (BW373U86) and (+)-4-[(R)-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N, N-diethylbenzamide (SNC80) failed to produce convulsive behavior demonstrating the absolute involvement of DOR-1 in this effect. In NIH Swiss mice expressing delta -opioid receptors, BW373U86 produced both antinociception and convulsive activity. These effects were antagonized by the putative delta 1-receptor-selective antagonist 7-benzylidenenaltrexone and the putative delta 2-receptor-selective antagonist naltriben. Tolerance developed to both the convulsive and antinociceptive effects of BW373U86. Tolerance to the convulsive, but not the antinociceptive, effects of BW373U86 was largely prevented when the antagonist naltrindole was given 20 min after each dose of the agonist in a 3-day treatment paradigm. The convulsive action of BW373U86 was also less sensitive than the antinociceptive action to treatment with the irreversible delta -antagonist naltrindole isothiocyanate. Collectively, these data suggest that the convulsive and antinociceptive activities of delta -agonists are mediated through the same receptor but that the receptor reserve for delta -mediated convulsive activity is greater than for delta -mediated antinociceptive activity.

0022-3565/02/3032-0723$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
P. N. Yadav, K. Chaturvedi, and R. D. Howells
Inhibition of Agonist-Induced Down-Regulation of the {delta}-Opioid Receptor with a Proteasome Inhibitor Attenuates Opioid Tolerance in Human Embryonic Kidney 293 Cells
J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1186 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Scherrer, P. Tryoen-Toth, D. Filliol, A. Matifas, D. Laustriat, Y. Q. Cao, A. I. Basbaum, A. Dierich, J.-L. Vonesh, C. Gaveriaux-Ruff, et al.
Knockin mice expressing fluorescent {delta}-opioid receptors uncover G protein-coupled receptor dynamics in vivo
PNAS, June 20, 2006; 103(25): 9691 - 9696.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Michael. J. Watson, J. D. S. Holt, S. J. O'Neill, K. Wei, W. Pendergast, G. J. Gross, P. J. Gengo, and K.-J. Chang
ARD-353 [4-((2R,5S)-4-(R)-(4-Diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2,5-dimethylpiperazin-1-ylmethyl)benzoic Acid], A Novel Nonpeptide {delta} Receptor Agonist, Reduces Myocardial Infarct Size without Central Effects
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 423 - 430.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. D. S. Holt, M. J. Watson, J. P. Chang, S. J. O'Neill, K. Wei, W. Pendergast, P. J. Gengo, and K.-J. Chang
DPI-221 [4-(({alpha}-S)-{alpha}-((2S,5R)-2,5-Dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)benzyl)-N,N-diethylbenzamide]: A Novel Nonpeptide {delta} Receptor Agonist Producing Increased Micturition Interval in Normal Rats
J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 601 - 608.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. M. Jutkiewicz, S. T. Kaminsky, K. C. Rice, J. R. Traynor, and J. H. Woods
Differential Behavioral Tolerance to the {delta}-Opioid Agonist SNC80 ([(+)-4-[({alpha}R)-{alpha}-[(2S,5R)-2,5-Dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley Rats
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 414 - 422.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. M. Jutkiewicz, N. P. Walker, J. E. Folk, K. C. Rice, P. S. Portoghese, J. H. Woods, and J. R. Traynor
Comparison of Peptidic and Nonpeptidic {delta}-Opioid Agonists on Guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTP{gamma}S) Binding in Brain Slices from Sprague-Dawley Rats
J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1314 - 1320.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.